Efficacy of galcanezumab for migraine prevention in patients with a medical history of anxiety and/or depression: a post hoc analysis of the phase 3, randomized, double-blind, placebo-controlled REGAIN, and pooled EVOLVE-1 and EVOLVE-2 studies (vol 60, pg 2202, 2020)

被引：0

作者：

Smitherman, T. A.

机构：

来源：

HEADACHE | 2022年 / 62卷 / 01期

关键词：

D O I：

10.1111/head.14109

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：114 / 116

页数：3

共 50 条

[1] Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies
Smitherman, Todd A.
Tietjen, Gretchen E.
Schuh, Kory
Skljarevski, Vladimir
Lipsius, Sarah
D'Souza, Deborah N.
Pearlman, Eric M.
HEADACHE, 2020, 60 (10): : 2202 - 2219
[2] Persistence of effect of galcanezumab in patients with episodic or chronic migraine: phase 3, randomized, double-blind, placebo controlled EVOLVE-1, EVOLVE-2 and REGAIN studies
Aurora, Sheena K.
Zhang, Qi
Stauffer, Virginia L.
JOURNAL OF HEADACHE AND PAIN, 2018, 19
[3] 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies
Rosen, Noah
Pearlman, Eric
Ruff, Dustin
Day, Kathleen
Nagy, Abraham Jim
HEADACHE, 2018, 58 (09): : 1347 - 1357
[4] Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies
Nichols, Russell
Doty, Erin
Sacco, Sara
Ruff, Dustin
Pearlman, Eric
Aurora, Sheena K.
HEADACHE, 2019, 59 (02): : 192 - 204
[5] 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies (vol 58, pg 1347, 2018)
Rosen, N.
Pearlman, E.
Ruff, D.
Nagy, Jim A.
HEADACHE, 2019, 59 (08): : 1428 - 1428
[6] GALCANEZUMAB EFFECTS IN ADULT PATIENTS WITH EPISODIC OR CHRONIC MIGRAINE ARE PERSISTENT: DATA FROM THREE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EVOLVE-1, EVOLVE-2, AND REGAIN STUDIES
Aurora, S.
Zhang, Q.
Stauffer, V.
CEPHALALGIA, 2018, 38 : 50 - 51
[7] Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies
Stefanie Förderreuther
Qi Zhang
Virginia L. Stauffer
Sheena K. Aurora
Miguel J. A. Láinez
The Journal of Headache and Pain, 2018, 19
[8] Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies
Foerderreuther, Stefanie
Zhang, Qi
Stauffer, Virginia L.
Aurora, Sheena K.
Lainez, Miguel J. A.
JOURNAL OF HEADACHE AND PAIN, 2018, 19
[9] Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)
Jessica Ailani
J. Scott Andrews
Mallikarjuna Rettiganti
Robert A. Nicholson
The Journal of Headache and Pain, 2020, 21
[10] Analysis of Initial Non Responders to Galcanezumab in Patients with Episodic or Chronic Migraine: Results from the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Trials
Nichols, Russell M.
Ruff, Dustin
Pearlman, Eric
Aurora, Sheena K.
JOURNAL OF HEADACHE AND PAIN, 2018, 19

← 1 2 3 4 5 →